Ocuphire Pharma Results Presentation Deck

8 DR/DME ZETA-1 Phase 2 Design Randomized, Double-Masked, Placebo-Controlled 24-Week Trial (Similar To Eylea P3 DR Trial) ZETA-1 25 US sites 90-100 participants with moderately severe-to-severe NPDR or mild PDR Noncentral DME is permitted in study eye and central DME allowed in fellow eye Eligibility Screening NPDR = non-proliferative diabetic retinopathy PDR = proliferative diabetic retinopathy 1:1 Randomization Week 0 APX3330 600mg/day (BID) Primary Endpoint NPDR = non-proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy ZETA-1 Clinical Trial is Sponsored by Ocuphire Pharma Week 4 Week 12 Placebo BID 103 Subjects Enrolled (FPFV Apr 2021- LPLV Aug 2022) Top Line Announced in Early 2023 Week 24 Endpoints Primary: % subjects with ≥ 2 step improvement on DRSS (Diabetic Retinopathy Severity Scale) at wk 24 Secondary: ● DRSS worsening* DRSS improvement* Progression to vision threatening complications Central subfield thickness (CST) Best Corrected Distance Visual Acuity (BCDVA) Rescue subjects • DME fellow eye status Safety and tolerability Exploratory: Labs / PK *Potential Phase 3 approvable endpoints Ocuphire

View entire presentation